Hey guys been gone from this forum for quite awhile after a long break of growing, but trying to get started again, glad its still hear. Not sure if this is the right section for this post but I'll ask anyway.
What kind of current research is being done with mushrooms/fungus at this time?
What kind of breakthroughs/studies/scientific endeavors right now?
I have an assignment in Bio class for a research paper on current topics and just looking for some ideas.
-------------------- If you always do what you always did you always get what you always got.
|
Here's some studies about psilocybin which have been conducted fairly recently, and a brief overview of each:
"Psilocybin in the treatment of cancer patients Psilocybin in the treatment of cancer patients Investigator: Charles Grob, MD, UCLA-Harbor Medical Center - Torrance, CA Contact: Marycie Hagerty Web: www.canceranxietystudy.org Sponsor: Heffter Grob has prepared a study investigating whether anxiety in the dying can be significantly reduced by the appropriate administration of psilocybin. Any attendant reduction in pain will also be measured. This study has enrolled 12 participants and is now complete. The researchers have published their results.. "
"Psilocybin in the Treatment of Obsessive-Compulsive Disorder Investigator: Francisco Moreno, MD University of Arizona, Tucson, USA Contact: Francisco Moreno, MD Sponsor: Heffter/MAPS This is the first FDA-approved study in more than 25 years to examine the use of psilocybin in a patient population. The principal investigators plan to study the use of psilocybin in 10 patients suffering from obsessive-compulsive disorder (OCD). They want to determine if they can replicate in a clinical study several published case reports of patients whose OCD symptoms were reduced after self- experimentation with psilocybin mushrooms. MAPS has paid $12,250 for the synthesis of one gram of psilocybin. Analytical data on this psilocybin has been submitted to FDA in March, 2001, with approval obtained from the FDA on May 9, 2001. DEA licenses received July 2, 2001. First patient was treated on November 27, 2001, and after enrolling nine subjects, the study is now complete. Dr. Moreno's research team is now looking at the data, and a publication will be forthcoming. Preliminary analyses have been performed, and the data has been presented at the Society of Biological Psychiatry, The American College of Neuropsychopharmacology, the New Clinical Drug Evaluation Unit, and the International Transpersonal Association (ITA) Annual Meetings. "
"Psilocybin: Basic Dose-Response Safety Studies Investigator: Franz Vollenweider, MD Psychiatric University Hospital Zurich, Switzerland Contact: Franz Vollenweider, MD Sponsor: Heffter Dr. Vollenweider's team have completed a series of basic research studies into the dose-response effects of psilocybin on physiological and psychological measures, cognition, sensorimotor gating, sequential behaviour, and brain activity in healthy human subjects. Fifty-six individuals were examined after a range of doses of psilocybin. A paper reporting the effects of placebo, very low, low, medium and high doses of psilocybin (45 -315 mcg/kg) in eight individuals has been published on-line in November 2003 and in print in March 2004. The researchers assessed subjective, physiological and neuroendocrine effects of psilocybin, including an assessment of attention and visual perception, and previous investigations have examined the contribution of serotonin and dopamine transmitter sytsems to producing the subjective effects of psilocybin. "
"The Concord Prison Experiment Experiment Follow-Up Investigator: Rick Doblin, Ph.D. Rick Doblin, PhD. This study, originally published in the Journal of Psychoactive Drugs [Oct-Dec 1998] is one in a series of long-term follow-ups to early psychedelic research that MAPS has sponsored. The original 1961-63 Harvard study lead by Dr. Timothy Leary investigated the utility of psilocybin in reducing rates of recidivism for prisoners. "
"The Good Friday Experiment Follow-Up Investigator: Rick Doblin, Ph.D. Contact: Rick Doblin, PhD This study, originally published in the Journal of Transpersonal Psychology [1991 Vol 23(1)] is one in a series of long-term follow-ups to early psychedelic research that MAPS has sponsored. The original 1962 Harvard study lead by Walter Pahnke investigated the utility of psilocybin in triggering a mystical experience."
"Psilocybin’s Effects on Cognition Investigator: Manfred Spitzer, MD, PhD et al. Psychiatrische Universitats Klinic, Heidelberg, Germany Human clinical study, completed and published. "
Source: http://www.maps.org/research/
I highly recommend you check out that website, loads more info to be had there! Good luck with your studies 
Note that it cost $12,250 to synthesize one gram of pure psilocybin. Holy smokes
--------------------
Edited by chutney (10/09/13 12:43 PM)
|